论文部分内容阅读
Objective Steroid hormone receptors(HRs),estrogen receptor(ER)and progesterone receptor(PR),are crucial biomarkers for clinical management in breast cancer.Both ER and PR are recommended to be detected for newly diagnosed breast cancer in clinical practice.Compared with HR-positive,HR-negative breast cancers have more aggressive features and worse prognosis.However,limited data are available regarding single HRpositive(ER+/PR-and ER-/PR+)breast cancer,making it difficult for treatment decision and survival prediction in patients with ER+/PR-or ER-/PR+.